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ABSTRACT
Objectives To examine the capacity of existing
cardiovascular disease (CVD) risk algorithms widely used
in primary care, to predict frailty.
Design Prospective cohort study. Risk algorithms at
baseline (1997–1999) were the Framingham CVD,
coronary heart disease and stroke risk scores, and the
Systematic Coronary Risk Evaluation.
Setting Civil Service departments in London, UK.
Participants 3895 participants (73% men) aged
45–69 years and free of CVD at baseline.
Main outcome measure Status of frailty at the end
of follow-up (2007–2009), based on the following
indicators: self-reported exhaustion, low physical activity,
slow walking speed, low grip strength and weight loss.
Results At the end of the follow-up, 2.8% (n=108) of
the sample was classiﬁed as frail. All four CVD risk
scores were associated with future risk of developing
frailty, with ORs per one SD increment in the score
ranging from 1.35 (95% CI 1.21 to 1.51) for the
Framingham stroke score to 1.42 (1.23 to 1.62) for the
Framingham CVD score. These associations remained
after excluding incident CVD cases. For comparison, the
corresponding ORs for the risk scores and incident
cardiovascular events varied between 1.36 (1.15 to
1.61) and 1.64 (1.50 to 1.80) depending on the risk
algorithm.
Conclusions The use of CVD risk scores in clinical
practice may also have utility for frailty prediction.
INTRODUCTION
Frailty is a clinically recognised geriatric syndrome
characterised by declines in functioning across an
array of physiological systems.1 Common symp-
toms of frailty are weight loss, exhaustion, low
physical activity, slow walking speed at ‘usual pace’
and low grip strength.1 In the elderly, there is
growing evidence that frailty predicts various
adverse health outcomes such as disability,2 institu-
tionalisation,2 falls,3 fractures,3 hospitalisation4 and
mortality.3 In order to design interventions for pre-
venting frailty, it is important to identify individuals
at risk of developing the syndrome.
In addition to cardiovascular disease (CVD),
there is increasing evidence to suggest that CVD
risk factors measured in midlife predict a wide
range of old-age health outcomes including cogni-
tive decline and dementia,5 late-life depression6
and disability.7 Although few large-scale prospective
studies have examined the association between
CVD risk factors and frailty, such a link is plausible
for at least two reasons. First, several studies have
shown a cross-sectional association between CVD
and frailty.2 In one cross-sectional study, subclinical
CVD diagnosed using non-invasive testing (carotid
ultrasound, ankle–arm index, electrocardiography,
echocardiography and cerebral MRI) was related to
frailty after excluding clinically diagnosed CVD.8
Second, several individual risk factors included in
multi-factorial prediction algorithms of CVD, such
as the Framingham score, have been associated
with frailty status: high blood pressure,9 diabetes,9
low high-density lipoprotein (HDL)-cholesterol
level10 and cigarette smoking.11
In this study, we hypothesised that CVD risk
scores used to assess 10-year risk of CVD would be
associated with subsequent frailty status in people
who were initially CVD-free. If a strong association
between CVD risk scores and frailty is conﬁrmed,
these scores, importantly already routinely adminis-
tered in clinical practice, would present a conveni-
ent way to identify individuals at an increased risk
of frailty later in life and in need of early prevent-
ive measures. Evidence from randomised controlled
trials suggest that exercise programmes12 and
selected drugs (eg, dehydroepiandrosterone13 and
testosterone14) can reverse frailty.
METHODS
Study population
Data were drawn from the Whitehall II study, an
ongoing longitudinal study of 10 308 (67% men)
London-based British civil servants aged 35–
55 years in 1985.15 Study inception (phase 1) took
place during 1985–1988 and involved a clinical
examination and self-administered questionnaire.
Subsequent phases of data collection have alter-
nated between postal questionnaire alone (phases 2
(1988–1990), 4 (1995–1996), 6 (2001), 8 (2006)
and 10 (2011)), and postal questionnaire accom-
panied by a clinical examination approximately
every 5 years (phases 3 (1991–1993), 5 (1997–
1999), 7 (2002–2004) and 9 (2007–2009)).
We utilised CVD risk factors measured at phase
5 (‘baseline’ for the purposes of our analyses) to
assess the risk of developing frailty at phase 9 when
the frailty components were ﬁrst measured. This
design provides a 10-year follow-up corresponding
to that of the CVD risk prediction models we uti-
lised.16–19
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CVD risk factors at baseline
Blood samples were collected following either an 8-h overnight
fast or at least a 4-h fast after a light fat-free breakfast. Serum
for lipid analyses was refrigerated at −4°C and assayed within
72 h. Total cholesterol was determined by an enzymatic proced-
ure using the automated cholesterol oxidase-phenol aminophe-
nazone (CHOD-PAP) method. Serum HDL-cholesterol
concentrations were measured from the supernatant after pre-
cipitation of non-HDL-cholesterol with phosphotungstate.
Systolic blood pressure was measured twice with the Hawksley
random zero sphygmomanometer in the sitting position after
5 min rest. We used the average of the two readings in the
present analyses. Participants reported the medications used in
the previous 14 days; responses were coded using the British
National Formulary codes.20 Antihypertensive therapy was
based on the use of the following drugs: diuretics, β-blockers,
ACE inhibitors, calcium channel blockers and other antihyper-
tensive drugs. Current smoking (yes/no) was ascertained by self-
report. Prevalent diabetes mellitus was deﬁned based on
reported doctor-diagnosed diabetes mellitus or use of diabetes
medication, or when participants had a baseline fasting plasma
glucose level >126 mg/dl (>7.0 mmol/l).21 Presence of atrial
ﬁbrillation and left ventricular hypertrophy was determined on
the ECG using the Minnesota Code:22 atrial ﬁbrillation is coded
as 8-3-1 and left ventricular hypertrophy as 3-1-0.
CVD risk scores at baseline
In addition to ﬁrst relating individual CVD risk factors to later
frailty risk, we also examined the predictive capacity of four
established CVD risk score algorithms: the Framingham CVD,18
coronary heart disease (CHD),19 stroke prediction models17 and
SCORE (systematic coronary risk evaluation).16 Table 1 sum-
marises all components included in the models, described
below.
Outcomes at follow-up
Frailty was measured using the Fried frailty scale at the end of
follow-up (phase 9, 2007–2009). This measure comprises the
following components: self-reported exhaustion, low physical
activity, slow walking speed, low grip strength and weight loss
(cut-offs for each component are based on that of Fried et al).1
A total frailty score was calculated by allocating a value of 1 to
each of the criteria if present, resulting in a range of 0–5.
Participants were classiﬁed as ‘frail’ if they had at least three out
of ﬁve of the frailty components; as ‘pre-frail’ if they had 1–2;
and as ‘non-frail’ if they had none of these components.1
Validated CVD outcomes (non-fatal CHD, non-fatal stroke, and
a composite of non-fatal CVD cases including both groups)
were assessed over the follow-up period (1997–1999 to 2007–
2009). More details are available in the supplementary web
appendix.
Statistical analyses
Each CVD risk factor at baseline was described according to the
frailty status (frail, pre-frail, and non-frail) at year 10 of
follow-up using the χ2 test, Fisher’s exact test or analysis of vari-
ance as appropriate. We then summarised these associations
using binary logistic regression analyses with frailty status
dichotomised: frail versus pre-frail/non-frail. As the mean risk
scores in men were systematically higher than those in women
(p values for all four scores <0.0001), we standardised these
risk scores into standard scores (mean=0, SD=1) in men and
women separately. The OR of being frail or pre-frail was esti-
mated per one SD increase (higher score represents greater
CVD risk) in the risk scores over the 10-year follow-up. As sex
did not modify the relation of the standardised risk scores with
frailty at follow-up (all p values for sex interaction >0.61), men
and women were combined in the analysis.
In examining the associations between individual risk factors
and later frailty, we initially produced sex-adjusted models and
then adjusted for the other risk factors to explore the independ-
ent effect of individual CVD risk factors with frailty. Binary
logistic regression models were then used to examine the impact
of a one SD increment in the risk scores on frailty at follow-up.
We also examined the association between the CVD risk scores
and incident cardiovascular events (CVD, CHD and strokes) to
compare the strength of their associations to that with frailty. In
addition, we conducted several sensitivity analyses. (1) To
examine whether the association between the risk scores and
frailty was mediated by underlying CVD, we estimated the
strength of this association after excluding incident CVD cases.
(2) To examine whether the association between the risk scores
and frailty was biased by missing data, we imputed data for
missing frailty status and individual CVD risk factors included
in the risk scores. This was done for participants eligible at
phase 5 and alive at the end of follow-up (n=7412) using the
method of multiple imputation by chained equations performed
with an SAS-callable software application, IVEware.23 (3) We
tested whether the CVD risk scores also predict ‘pre-frailty’ in a
cohort excluding the frailty cases (see supplementary web
appendix). Finally, to explore the extent to which the relation-
ship between the risk scores and frailty was driven by speciﬁc
CVD risk factors included in the scores, analyses on the risk
scores–frailty associations were adjusted individually for each of
their risk factors (see supplementary web appendix, table S1). A
greater attenuation in the association after adjustment indicates
a greater contribution of that speciﬁc risk factor. All analyses
were performed with SAS V.9.1.
RESULTS
Of the 7870 study members who participated at phase 5, a total
of 3895 participants (1037 women) aged 45–69 years consti-
tuted the analytic sample (ﬁgure 1). Compared with participants
Table 1 Composition of the SCORE and Framingham CVD, CHD and stroke risk algorithms
Score Country Sex Age Total C HDL-C SBP DBP AHTD Smoking Diabetes CVD AF LVH
Framingham CVD USA + + + + + + + +
Framingham CHD USA + + + + + + + +
Framingham stroke USA + + + + + + + + +
SCORE Europe + + + + +
AHTD, antihypertensive drug; AF, atrial fibrillation; CVD, cardiovascular disease; CHD, coronary heart disease; C, cholesterol; DBP, diastolic blood pressure; LVH, left ventricular
hypertrophy; SBP, systolic blood pressure; SCORE, Systematic Coronary Risk Evaluation.
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alive at phase 9 but excluded (owing to non-participation at
phases 5 and 9, prior history of CVD at phase 5, and missing
data on the CVD risk scores or the frailty scale, total n=3517),
persons included in the analytic sample (n=3895) were
1.1 years younger (p<0.0001), less likely to be female (26.6%
vs 34.5%, p<0.0001) and less likely to be from the lower socio-
economic group (10.0% vs 20.0%, p<0.0001) (see supplemen-
tary web appendix, table S2).
In table 2 we present the baseline characteristics of partici-
pants according to frailty status at the end of follow-up, on
average 10.5 years (SD=0.5) after the measurement of CVD
risk scores. Of the 3895 participants, 2.8% were classiﬁed as
frail, 37.1% as pre-frail and 60.1% as non-frail. In comparison
with non-frail participants, frail participants were more likely to
be older, female, use antihypertensive treatment, smoke and
have diabetes. Frail participants were also more likely to have
experienced a CVD event during the follow-up relative to their
non-frail counterparts (incidence 16.7% vs 8.5%, p=0.01).
In table 3, we present the association between the individual
CVD risk factors at baseline and frailty at follow-up. In the
model including all risk factors, only two were independently
associated with future frailty: increased age and use of antihy-
pertensive treatment. Thus, a one SD increment in age
(5.9 years for men and women) increased the odds of being frail
by 56% (OR=1.56, 95% CI 1.28 to 1.92) and using an antihy-
pertensive treatment increased the odds by 77% (OR=1.77,
95% CI 1.10 to 2.94).
Table 4 shows the association of a one SD increment in the
CVD risk scores with future frailty and cardiovascular events.
All risk scores had a similar strength of association with frailty,
with the ORs ranging from 1.35 (95% CI 1.21 to 1.51) for the
Framingham stroke risk score to 1.42 (95% CI 1.23 to 1.62) for
the Framingham CVD risk score. As expected, the association of
the CVD risk scores was stronger in relation to predicting CVD
events, with ORs ranging from 1.36 (95% CI 1.15 to 1.61) for
the Framingham stroke risk score to 1.64 (95% CI 1.50 to
1.80) for the Framingham CVD risk score. The strength of the
association between the CVD risk scores and frailty remained
essentially the same after exclusion of incident CVD cases, and
in multiple imputation (see supplementary web appendix, table
S3). The CVD risk scores also predicted pre-frailty although to
a lesser extent than for frailty (see supplementary web appendix,
table S4).
In supplementary web appendix, table S1, we present results
of analyses in which the four CVD risk scores were adjusted for
each of their risk factors. The association between risk scores
and frailty was attenuated after adjustments for age and antihy-
pertensive treatment, but is still statistically signiﬁcant, suggest-
ing that this association was not driven by any speciﬁc risk
factor.
DISCUSSION
Our main ﬁnding from this cohort of middle aged individuals
was that four different CVD risk scores were associated with an
elevated risk of frailty. Thus, one sex-speciﬁc SD increment in
the risk scores increased the odds of being classiﬁed as frail at
the end of the 10-year follow-up by 35–42%. The strength of
this association was only slightly diminished after exclusion of
cases of CVD during the follow-up, suggesting that the predict-
ive risk score-frailty associations were not driven by co-morbid
CVD. Furthermore, we found that these scores stratiﬁed the risk
of developing frailty. To the best of our knowledge, the link
between scores from CVD risk factor engines and future frailty
has not been examined.
Although initially designed to predict CVD, our results
suggest that the CVD risk scores also appear to be a predictive
marker of general health such as frailty status. In a previous
study, the Framingham CVD risk score was also found to be
associated with cognitive decline.5 Our ﬁnding in relation to
frailty is plausible given that each risk factor—age, total choles-
terol, HDL-cholesterol, systolic blood pressure, smoking and
diabetes—included in these scores has also been shown to be
associated with various other health outcomes including cancer,
which, after CVD, is the second leading cause of death in eco-
nomically developed countries.24 One plausible mechanism
linking risk scores to both CVD and frailty is the presence of
atherosclerosis in arteries and related chronic systemic inﬂamma-
tion.25 Atherosclerotic processes can prevent blood ﬂow
through the coronary artery, causing CVD,25 and through the
muscles, causing sarcopenia, a clinical feature of frailty.26
We found that the proportion of frailty was higher in women
than men (5.1% versus 1.9%, respectively). This is in agreement
with previous ﬁndings,27 but opposite to what one might expect
for CVD, which is more common in men in late middle-age. In
our study, the incidence of CVD was 9.9% in men versus 5.7%
in women. A potential explanation for the higher incidence of
frailty in women pertains to differences in biology between the
sexes, with men having greater bone mineral density and muscle
mass in old age.28
Figure 1 Flow of study members through the data collection phases
in Whitehall II.
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This study has some limitations. First, we identiﬁed frailty
cases by using a measure operationalised by Fried et al,1 but a
recent review identiﬁed that there are more than 20 alternative
measures of frailty.29 Although there are no gold standard mea-
sures, the measure by Fried et al is the most widely used.
Second, we assessed CVD risk at the mean age of 55 years. It
remains unclear whether our ﬁndings are generalisable to other
age groups because at older ages low rather than high levels of
some cardiovascular risk factors (total cholesterol, low-density
lipoprotein (LDL)-cholesterol and systolic blood pressure) are
associated with poor health outcome, as assessed by activity
daily living disability, hospitalisation, functional performance
and mortality.30 In relation to CVD prediction, the risk scores
are not recommended to be used at older ages (>75 years); the
validity of these scores as risk markers of frailty should be exam-
ined in that age in future studies. Third, approximately half of
the study members who participated at phase 5 were excluded
from the analysis due to death, non-participation, loss to
follow-up or missing data. Our sensitivity analysis suggests this
is not a major source of bias because the results using the mul-
tiple multivariate imputation method were largely similar to
those reported in the main analysis. However, we cannot rule
out bias arising from attrition not covered by the
missingness-at-random assumption. Finally, our study sample
consisted of middle-aged civil servants, limiting the generalis-
ability of our ﬁndings. These limitations can be compared to the
main strength of our study, which resides in the use of prospect-
ively collected data given that previous studies that have exam-
ined the association between CVD or its individual risk factors
and frailty used cross-sectional data.2 8 9 Our results suggest a
relationship between the CVD risk scores and frailty that is
independent of existing CVD. However, these ﬁndings, based
on observational data, do not provide information about causal-
ity as we cannot rule out the confounding effect of unmeasured
risk factors.
Besides the clinical utility of CVD risk scores—Framingham
CVD, CHD, stroke or SCORE—in predicting risk of cardiovas-
cular death and disease, our results suggest that they may also
help to identify middle-aged persons who will beneﬁt from
interventions designed to prevent frailty. As such, the use of
CVD risk scores in clinical practice may also have utility for
frailty prediction.
Table 2 Characteristics of participants in the analytical sample (n=3895)
All
Frailty status at follow-up
p Value*Not frail Pre-frail Frail
Number 3895 2342 1445 108
Age, years, mean (SD) 55.2 (5.9) 54.9 (5.7) 55.5 (6.1) 57.9 (6.5) <0.0001
Sex, n (%)
Male 2858 (73.4) 1821 (77.8) 982 (68.0) 55 (50.9) <0.0001
Female 1037 (26.6) 521 (22.4) 463 (32.0) 53 (49.1)
Total cholesterol, mmol/l, mean (SD) 5.92 (1.05) 5.91 (1.02) 5.94 (1.09) 5.99 (1.03) 0.22
HDL cholesterol, mmol/l, mean (SD) 1.46 (0.39) 1.47 (0.39) 1.45 (0.38) 1.47 (0.39) 0.21
Systolic blood pressure, mm Hg, mean (SD) 122.7 (16.0) 122.3 (15.7) 123.3 (16.3) 124.5 (16.1) 0.03
Diastolic blood pressure, mm Hg, mean (SD) 77.6 (10.3) 77.5 (10.2) 77.8 (10.5) 78.4 (11.6) 0.28
Antihypertensive treatment, n (%)
No 3515 (90.2) 2137 (91.3) 1293 (89.5) 85 (78.7) <0.0001
Yes 380 (9.8) 205 (8.7) 152 (10.5) 23 (21.3)
Smoking, n (%)
No 3593 (92.3) 2185 (93.3) 1313 (90.9) 95 (88.0) 0.006
Yes 302 (7.8) 157 (6.7) 132 (9.1) 13 (12.0)
Diabetes, n (%)
No 3755 (96.4) 2273 (97.1) 1381 (95.6) 101 (93.5) 0.02
Yes 140 (3.6) 69 (3.0) 64 (4.4) 7 (6.5)
Atrial fibrillation, n (%)
No 3882 (99.7) 2335 (99.7) 1439 (99.6) 108 (100.0) -
Yes 13 (0.3) 7 (0.3) 6 (0.4) 0
Left ventricular hypertrophy, n (%)
No 3667 (94.2) 2214 (94.5) 1356 (93.8) 97 (89.8) 0.10
Yes 228 (5.8) 128 (5.5) 89 (6.2) 11 (10.2)
Incident CVD at follow-up, n (%)
No 3552 (91.2) 2143 (91.5) 1319 (91.3) 90 (83.3) 0.01
Yes 343 (8.8) 199 (8.5) 126 (8.7) 18 (16.7)
Incident CHD at follow-up, n (%)
No 3582 (92.0) 2165 (92.4) 1324 (91.6) 93 (86.1) 0.05
Yes 313 (8.0) 177 (7.6) 121 (8.4) 15 (13.9)
Incident stroke at follow-up, n (%)
No 3856 (99.0) 2316 (98.9) 1436 (99.4) 104 (96.3) 0.01
Yes 39 (1.1) 26 (1.1) 9 (0.6) 4 (3.7)
*p for heterogeneity.
CVD, cardiovascular disease; CHD, coronary heart disease.
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